Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma.

ABSTRACT:

Background

Blood eosinophil count is usually employed as a predictive and response biomarker for mepolizumab treatment. However, its decrease is not always associated with an improvement in asthma symptoms. The aim of this work is to study the effect of mepolizumab in the activation status and functional phenotype of circulating eosinophils.

Methods

Samples from healthy controls (N = 15) and patients with severe eosinophilic asthma (N = 15) before and after 4, 16 and 32 weeks of mepolizumab treatment (anti-IL5 mAb; 100 mg s.c./4 weeks) were screened. Demographic, clinical, hematological and biochemical characteristics were collected. Activation and functional phenotype of peripheral blood eosinophils was analyzed by flow cytometry. sCD62L in serum was measured by ELISA. Targ

SUBMITTER: Miguens-Suarez P 

PROVIDER: S-EPMC12695602 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature